organization · Reporting owner
Atlas Venture Fund VII L P
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Viridian Therapeutics, Inc.\DEMGEN · Entity 4316 | 10% owner | February 13, 2017 | February 13, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Viridian Therapeutics, Inc.\DE
Report date February 13, 2017 · Filed February 13, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,142,580 |
Reported balance
Holding disclosure · report date 2017-02-13 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 3,142,580 F1: Shares of common stock of the corporation then known as Miragen Therapeutics, Inc. ("Old Miragen") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of October 31, 2016, by and among the Issuer, Signal Merger Sub, Inc. and Old Miragen (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of common stock was converted into 0.7031 shares of the Issuer's common stock. F2: Represents 4,469,607 shares of common stock of Old Miragen prior to conversion pursuant to the Merger Agreement including: 83,250 shares of common stock of Old Miragen; and shares of common stock of Old Miragen issued upon the conversion of 2,661,454 shares of Series A preferred stock of Old Miragen, 479,401 shares of Series B preferred stock of Old Miragen and 1,245,502 shares of Series C preferred stock of Old Miragen. Immediately prior to the effective time of the merger, each share of Old Miragen preferred stock converted into one share of Old Miragen's common stock. F3: The shares are held by Atlas Venture Fund VII, L.P. ("Atlas Venture VII"). Atlas Venture Associates VII, L.P. ("AVA VII LP") is the general partner of Atlas Venture VII, and Atlas Venture Associates VII, Inc. ("AVA VII Inc.") is the general partner of AVA VII LP. Each of AVA VII LP and AVA VII Inc. disclaims Section 16 beneficial ownership of the securities held by Atlas Venture VII, except to the extent of its pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares of common stock of the corporation then known as Miragen Therapeutics, Inc. ("Old Miragen") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of October 31, 2016, by and among the Issuer, Signal Merger Sub, Inc. and Old Miragen (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of common stock was converted into 0.7031 shares of the Issuer's common stock.
F2: Represents 4,469,607 shares of common stock of Old Miragen prior to conversion pursuant to the Merger Agreement including: 83,250 shares of common stock of Old Miragen; and shares of common stock of Old Miragen issued upon the conversion of 2,661,454 shares of Series A preferred stock of Old Miragen, 479,401 shares of Series B preferred stock of Old Miragen and 1,245,502 shares of Series C preferred stock of Old Miragen. Immediately prior to the effective time of the merger, each share of Old Miragen preferred stock converted into one share of Old Miragen's common stock.
F3: The shares are held by Atlas Venture Fund VII, L.P. ("Atlas Venture VII"). Atlas Venture Associates VII, L.P. ("AVA VII LP") is the general partner of Atlas Venture VII, and Atlas Venture Associates VII, Inc. ("AVA VII Inc.") is the general partner of AVA VII LP. Each of AVA VII LP and AVA VII Inc. disclaims Section 16 beneficial ownership of the securities held by Atlas Venture VII, except to the extent of its pecuniary interest therein, if any.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Larimar Therapeutics, Inc.
Report date June 29, 2018 · Filed July 02, 2018
Jointly reported with Atlas Venture Associates VII, L.P., Atlas Venture Associates VII, Inc.
Section 16 reporting ended · disclosed 2018-07-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,506,184 |
Reported balance
After 2018-06-29 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2018-06-29 · Other · Disposed 1,126,546 · Balance 3,506,184 F1: On June 29, 2018, Atlas Venture Fund VII LP ("Atlas Venture VII") distributed, for no consideration, 1,126,546 shares of the Issuer's Common Stock, pro-rata, to its partners, including its limited partners and its general partner, in accordance with the exemptions afforded by Rule 16a-9 and Rule 16a-13 of the Securities Exchange Act of 1934, as amended. The distribution was effected pursuant to a Rule 10b5-1 plan adopted by Atlas Venture VII on December 22, 2017. F3: These shares are held directly by Atlas Venture VII. The general partner of Atlas Venture VII is AVA VII LP, and the general partner of AVA VII LP is Atlas Venture Associates VII, Inc. ("AVA VII Inc."). AVA VII LP and AVA VII Inc. disclaim Section 16 beneficial ownership of such shares, except to the extent of a pecuniary interest, if any, therein. This report shall not be deemed an admission that the reporting persons are the beneficial owners of such securities for the purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | Direct | 11 |
Reported balance
After 2018-06-29 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2018-06-29 · Other · Disposed 234,321 · Balance 11 F2: On June 29, 2018, Atlas Venture Associates VII LP ("AVA VII LP"), the general partner of Atlas Venture VII distributed, for no consideration, 234,421 shares of the Issuer's Common Stock, pro-rata, to its partners, including its limited partners and its general partner, in accordance with the exemptions afforded by Rule 16a-9 and Rule 16a-13 of the Securities Exchange Act of 1934, as amended. The distribution was effected pursuant to a Rule 10b5-1 plan adopted by AVA VII on December 22, 2017. F1: On June 29, 2018, Atlas Venture Fund VII LP ("Atlas Venture VII") distributed, for no consideration, 1,126,546 shares of the Issuer's Common Stock, pro-rata, to its partners, including its limited partners and its general partner, in accordance with the exemptions afforded by Rule 16a-9 and Rule 16a-13 of the Securities Exchange Act of 1934, as amended. The distribution was effected pursuant to a Rule 10b5-1 plan adopted by Atlas Venture VII on December 22, 2017. F4: These shares are held directly by AVA VII LP. The general partner of AVA VII LP is AVA VII Inc. AVA VII Inc. disclaims Section 16 beneficial ownership of such shares, except to the extent of a pecuniary interest, if any, therein. This report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for the purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 29, 2018, Atlas Venture Fund VII LP ("Atlas Venture VII") distributed, for no consideration, 1,126,546 shares of the Issuer's Common Stock, pro-rata, to its partners, including its limited partners and its general partner, in accordance with the exemptions afforded by Rule 16a-9 and Rule 16a-13 of the Securities Exchange Act of 1934, as amended. The distribution was effected pursuant to a Rule 10b5-1 plan adopted by Atlas Venture VII on December 22, 2017.
F2: On June 29, 2018, Atlas Venture Associates VII LP ("AVA VII LP"), the general partner of Atlas Venture VII distributed, for no consideration, 234,421 shares of the Issuer's Common Stock, pro-rata, to its partners, including its limited partners and its general partner, in accordance with the exemptions afforded by Rule 16a-9 and Rule 16a-13 of the Securities Exchange Act of 1934, as amended. The distribution was effected pursuant to a Rule 10b5-1 plan adopted by AVA VII on December 22, 2017.
F3: These shares are held directly by Atlas Venture VII. The general partner of Atlas Venture VII is AVA VII LP, and the general partner of AVA VII LP is Atlas Venture Associates VII, Inc. ("AVA VII Inc."). AVA VII LP and AVA VII Inc. disclaim Section 16 beneficial ownership of such shares, except to the extent of a pecuniary interest, if any, therein. This report shall not be deemed an admission that the reporting persons are the beneficial owners of such securities for the purposes of Section 16 or for any other purpose.
F4: These shares are held directly by AVA VII LP. The general partner of AVA VII LP is AVA VII Inc. AVA VII Inc. disclaims Section 16 beneficial ownership of such shares, except to the extent of a pecuniary interest, if any, therein. This report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for the purposes of Section 16 or for any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 29, 2018 Filed Jul 2, 2018 16:01 UTC | Larimar Therapeutics, Inc. ZFGN · Entity 5634 | OtherCommon Stock | 234,321 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-043521 · a4.xml · nonDerivative · entry 2 Atlas Venture Fund VII L P · CIK 0001346450 · 10% owner Atlas Venture Associates VII, L.P. · CIK 0001377726 · 10% owner Atlas Venture Associates VII, Inc. · CIK 0001377725 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11 F2 · kind: On June 29, 2018, Atlas Venture Associates VII LP ("AVA VII LP"), the general partner of Atlas Venture VII distributed, for no consideration, 234,421 shares of the Issuer's Common Stock, pro-rata, to its partners, including its limited partners and its general partner, in accordance with the exemptions afforded by Rule 16a-9 and Rule 16a-13 of the Securities Exchange Act of 1934, as amended. The distribution was effected pursuant to a Rule 10b5-1 plan adopted by AVA VII on December 22, 2017. F1 · price: On June 29, 2018, Atlas Venture Fund VII LP ("Atlas Venture VII") distributed, for no consideration, 1,126,546 shares of the Issuer's Common Stock, pro-rata, to its partners, including its limited partners and its general partner, in accordance with the exemptions afforded by Rule 16a-9 and Rule 16a-13 of the Securities Exchange Act of 1934, as amended. The distribution was effected pursuant to a Rule 10b5-1 plan adopted by Atlas Venture VII on December 22, 2017. F4 · ownership.direct: These shares are held directly by AVA VII LP. The general partner of AVA VII LP is AVA VII Inc. AVA VII Inc. disclaims Section 16 beneficial ownership of such shares, except to the extent of a pecuniary interest, if any, therein. This report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for the purposes of Section 16 or for any other purpose. Read SEC document |
| June 29, 2018 Filed Jul 2, 2018 16:01 UTC | Larimar Therapeutics, Inc. ZFGN · Entity 5634 | OtherCommon Stock | 1,126,546 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-043521 · a4.xml · nonDerivative · entry 1 Atlas Venture Fund VII L P · CIK 0001346450 · 10% owner Atlas Venture Associates VII, L.P. · CIK 0001377726 · 10% owner Atlas Venture Associates VII, Inc. · CIK 0001377725 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,506,184 F1 · kind: On June 29, 2018, Atlas Venture Fund VII LP ("Atlas Venture VII") distributed, for no consideration, 1,126,546 shares of the Issuer's Common Stock, pro-rata, to its partners, including its limited partners and its general partner, in accordance with the exemptions afforded by Rule 16a-9 and Rule 16a-13 of the Securities Exchange Act of 1934, as amended. The distribution was effected pursuant to a Rule 10b5-1 plan adopted by Atlas Venture VII on December 22, 2017. F1 · price: On June 29, 2018, Atlas Venture Fund VII LP ("Atlas Venture VII") distributed, for no consideration, 1,126,546 shares of the Issuer's Common Stock, pro-rata, to its partners, including its limited partners and its general partner, in accordance with the exemptions afforded by Rule 16a-9 and Rule 16a-13 of the Securities Exchange Act of 1934, as amended. The distribution was effected pursuant to a Rule 10b5-1 plan adopted by Atlas Venture VII on December 22, 2017. F3 · ownership.direct: These shares are held directly by Atlas Venture VII. The general partner of Atlas Venture VII is AVA VII LP, and the general partner of AVA VII LP is Atlas Venture Associates VII, Inc. ("AVA VII Inc."). AVA VII LP and AVA VII Inc. disclaim Section 16 beneficial ownership of such shares, except to the extent of a pecuniary interest, if any, therein. This report shall not be deemed an admission that the reporting persons are the beneficial owners of such securities for the purposes of Section 16 or for any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.